Vivani says its implant delivers medication steadily over long periods of time.

April 26, 2010 (Barcelona, Spain) — The gonadotropin-releasing hormone (GnRH) agonist histrelin acetate (VantasR), administered as a 50 mg subdermal implant once yearly, retained its effectiveness ...

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...

Vivani’s NanoPortal technology delivers medication steadily over long periods of time.

ALAMEDA, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including its lead asset ...

There are three progestin-containing subdermal implants. The first implant to be developed was Norplant, which is no longer being manufactured. Norplant had six levonorgestrel-containing capsules, and ...

Vivani’s GLP-1 (exenatide) implant produced sham-implant adjusted liver fat reduction of 82% in an obese mouse model from a single administration with expected twice-yearly dosing Vivani previously ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. The arm model ("Subdermal Implant ...

Project LAYA trains over 60 healthcare providers to expand access to long-acting subdermal contraceptive implants.